I'm A Patient
I'm A Provider
Overview
Patients looking for clinics that offer microcurrent therapy for dry AMD can start by asking their current optometrist or ophthalmologist for a referral. If the provider does not offer the therapy directly, they may know which local practices do. Device manufacturers often maintain a publicly searchable clinic locator, and professional associations such as the Canadian Optometric Association or provincial eye care bodies can also point patients to practices with the technology.1
Because microcurrent therapy is a relatively specialized intervention, not every general optometry practice will offer it. Patients may need to contact multiple clinics or travel to access it, especially in rural areas. A brief phone call or website search can help patients find a provider.
What Is Microcurrent Therapy for Macular Degeneration?
Microcurrent therapy delivers low-level electrical stimulation to the tissues around the eye using electrodes placed on the skin. The treatment is noninvasive, conducted in a clinical setting, and does not require injections, drops or surgery. Everyone is different, but sessions are often brief and well-tolerated by patients.
It is important to distinguish between devices with formal regulatory approval for treating dry AMD and those without. In Canada, a Health Canada medical device licence means the device has met the applicable regulatory requirements for safety and effectiveness for its authorized intended use. The type and amount of evidence Health Canada reviews depends on the device and its risk classification. Unapproved devices or unregulated wellness treatments using the term “microcurrent” are not equivalent and should not be treated as such.4
How to Locate Microcurrent Therapy
Begin with Your Current Eye Care Provider
Start by asking the optometrist or ophthalmologist already managing your dry AMD whether they offer device-based microcurrent therapy or can refer you to a practice that does. Managing AMD often means that the patient-provider relationship should include access to a full range of current options.
Use a Manufacturer’s Clinic Locator
Some device manufacturers maintain online clinic finders for patients, allowing searches by city, province or postal code. Manufacturer clinic locators can help patients identify practices that offer the device, although listings may not always reflect a clinic’s current availability.
When using a clinic locator, confirm during your initial call that the device is still in active use and that the clinic is taking new patients. Locator databases are not always updated in real time.
Contact Professional Associations
Professional associations and regulatory colleges can be useful sources of information about licensed eye care professionals in your area. However, they may not maintain lists of clinics offering specific AMD technologies, so patients should confirm directly with the practice whether the treatment is available.
Ask in Patient Communities
Online forums, support groups, and patient communities for AMD can be a useful informal source of clinic recommendations, particularly from people who have already gone through the process of finding a provider. This information is not clinically vetted, but it can give a starting point for which practices in a region are actively offering device-based therapy.
Any recommendation from a patient community should be followed up with direct verification. Confirm the device is authorized, the clinician is licensed and that the clinic conducts a proper eligibility assessment before beginning treatment.
What to Look for in a Clinic
Regulatory Authorization
The most important criterion is whether the clinic uses a device that holds regulatory approval for treating dry AMD in the country where treatment is delivered. In Canada, the relevant standard is a Health Canada Medical Device Licence. You can ask the clinic directly what device they use and whether Health Canada has authorized it to treat dry AMD. A qualified clinic should be able to answer this question clearly.4
Clinical Eligibility Assessment
A reputable clinic should conduct a proper clinical assessment before offering treatment. This typically includes reviewing the patient’s AMD stage and history, recent retinal imaging such as OCT and current best-corrected visual acuity measurements. Eligibility criteria for authorized devices are specific: MacuMira, for example, was studied in patients with visual acuity ranging from 20/50 to 20/200, and the treating clinician should discuss how the patient’s baseline fits the evidence.2
A clinic that offers to begin treatment without reviewing current clinical records or conducting a new assessment should be approached with caution. Device-based therapy for dry AMD should be used as part of a managed care plan, not as a standalone wellness service.
Clinician Qualifications
Treatment should be supervised by a licensed eye care professional, a registered optometrist or ophthalmologist with the authority to assess AMD stage, interpret retinal imaging and manage any concerns that arise during or after the treatment course. Some clinics may have trained staff assist with or administer treatment under the supervision of the responsible eye care professional, depending on applicable provincial requirements and the device’s instructions for use.
Transparent Discussion of Outcomes
Before beginning treatment, the clinic should clearly explain what the therapy is designed to achieve, what the published evidence shows, and what the limitations are. Authorized microcurrent therapy devices are indicated to improve visual function, specifically measures such as visual acuity and contrast sensitivity, not to halt progression or reverse disease. Question any clinic that makes unsupported claims about stopping progression or guaranteeing results.2
What to Ask at Your First Consultation
- What device do you use and what is its regulatory authorization status in Canada?4
- Am I a suitable candidate based on my current AMD stage?2
- How many treatments are typically involved and what does a standard course of treatment look like?
- What outcomes have you observed in patients you have treated, and how does that compare with the published trial data?
- How will we measure whether the treatment is working for me?
- Will this therapy fit into my existing AMD management plan, including my monitoring schedule and any supplements I am taking?
- What is the cost and are there payment options such as health spending accounts?
What to Expect from Treatment
Published evidence for authorized device-based therapy shows improvements in both visual acuity and contrast sensitivity measured in a clinical trial setting. Every patient responds differently to therapy, based on individual disease characteristics, baseline acuity and other factors.2
MacuMira is a Health Canada-authorized device-based therapy intended to improve visual function. MacuMira is not generally presented as a one-time treatment. Treatments are typically followed up to help maintain visual improvements, with the schedule determined by the treating eye care professional.
Patients whose baseline visual acuity is better than 20/50 may experience a ceiling effect, meaning the scope for measurable improvement is smaller because their starting point is closer to the upper range studied in the trial. This does not mean the therapy is unsuitable for them, but it does mean the conversation about expected benefit should be calibrated to their specific situation.
Conclusion
Clinics offering microcurrent therapy for dry AMD are available across Canada, but not every general eye care practice offers the treatment. The most reliable routes are a referral from an existing provider, a manufacturer’s clinic locator or direct outreach to optometry practices with a special interest in AMD. Before beginning treatment, confirm that the clinic uses a device with Health Canada authorization, conducts a proper eligibility assessment and can clearly explain the evidence behind the therapy.
Disclaimer
This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Patients should consult a qualified eye care professional to determine whether microcurrent therapy is appropriate for their specific condition.
Glossary
Microcurrent therapy: Low-level electrical stimulation applied non-invasively to tissues near the eye. Used in approved devices to improve visual function in patients with dry AMD.
Health Canada Medical Device Licence: Regulatory authorization issued by Health Canada confirming that a medical device meets Canadian safety and efficacy standards for its approved indication.
Dry AMD (dry age-related macular degeneration): A progressive retinal condition affecting the macula. The most common form of AMD, distinct from wet AMD.
Wet AMD: A form of AMD involving abnormal blood vessel growth beneath the retina, requiring different treatment from dry AMD. Approved microcurrent therapy devices are not indicated for wet AMD.
MacuMira: An approved medical device indicated to improve visual function in patients with dry AMD, delivered as low-level electrical stimulation in a clinical setting under the supervision of an eye care professional. Not indicated for wet AMD.
Optical coherence tomography (OCT): A non-invasive retinal imaging technology that produces detailed cross-sectional images of the macula. The standard tool for staging and monitoring dry AMD.
ETDRS scale: The Early Treatment Diabetic Retinopathy Study visual acuity measurement system, scored letter by letter. The standard outcome measure in AMD clinical trials.
Contrast sensitivity: The ability to distinguish objects from their background at varying contrast levels. Often affected by dry AMD independently of high-contrast visual acuity.
Retinal pigment epithelium (RPE): A layer of cells beneath the photoreceptors in the retina that supports photoreceptor health and function. Deterioration of the RPE is a central feature of dry AMD.
References
1. Age-Related Macular Degeneration (AMD). Canadian Ophthalmological Society. Date not listed. Accessed June 2026. https://www.seethepossibilities.ca/eye-health/age-related-macular-degeneration/.
2. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Parkinson KM, Sayre EC, Tobe SW. International Journal of Retina and Vitreous. Published May 2023. Accessed June 2026. https://macumira.com/wp-content/uploads/2025/07/MacuMira-Clinical-Trial.pdf.
3. Age-Related Macular Degeneration. National Eye Institute, National Institutes of Health. Last reviewed November 2023. Accessed June 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration.
4. Medical Device Licences. Health Canada. Date not listed. Accessed June 2026. https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/licences.html.
5. Understanding Macular Degeneration. American Academy of Ophthalmology. Published November 2025. Accessed June 2026. https://www.aao.org/eye-health/diseases/amd-macular-degeneration.
